Textbook of Personalized Medicine - Second Edition [2015]

136

Table 4.9 (continued)

Drug Therapeutic area Gene Referenced subgroup
Chlorpropamide Endocrinology G6PD G6PD defi cient
Cisplatin Oncology TPMT TPMT intermediate or poor
metabolizers
Citalopram (1) Psychiatry CYP2C19 CYP2C19 poor
metabolizers
Citalopram (2) Psychiatry CYP2D6 CYP2D6 poor metabolizers
Clobazam Neurology CYP2C19 CYP2C19 poor
metabolizers
Clomipramine Psychiatry CYP2D6 CYP2D6 poor metabolizers
Clopidogrel Cardiology CYP2C19 CYP2C19 intermediate or
poor metabolizers
Clozapine Psychiatry CYP2D6 CYP2D6 poor metabolizers
Codeine Anesthesiology CYP2D6 CYP2D6 poor metabolizers
Crizotinib Oncology ALK ALK gene rearrangement
positive
Dabrafenib (1) Oncology BRAF BRAF V600E mutation
positive
Dabrafenib (2) Oncology G6PD G6PD defi cient
Dapsone Dermatology G6PD G6PD defi cient
Dasatinib Oncology BCR/ABL1 Philadelphia chromosome
(t(9;22)) positive; T315I
mutation-positive
Denileukin diftitox Oncology IL2RA CD25 antigen positive
Desipramine Psychiatry CYP2D6 CYP2D6 poor metabolizers
Dexlansoprazole (1) Gastroenterology CYP2C19 CYP2C19 poor
metabolizers
Dexlansoprazole (2) Gastroenterology CYP1A2 CYP1A2 genotypes
Dextromethorphan
and Quinidine

Neurology CYP2D6 CYP2D6 poor metabolizers

Diazepam Psychiatry CYP2C19 CYP2C19 poor
metabolizers
Doxepin Psychiatry CYP2D6 CYP2D6 poor metabolizers
Drospirenone and
ethinyl estradiol

Neurology CYP2D6 CYP2D6 poor metabolizers

Eltrombopag (1) Hematology F5 Factor V Leiden carriers
Eltrombopag (2) Hematology SERPINC1 Antithrombin III defi cient
Erlotinib (1) Oncology EGFR EGFR protein expression
positive
Erlotinib (2) Oncology EGFR EGFR exon 19 deletion or
exon 21 substitution
(L858R) positive
Esomeprazole Gastroenterology CYP2C19 CYP2C19 poor
metabolizers
Everolimus (1) Oncology ERBB2 HER2 protein
overexpression positive
Everolimus (2) Oncology ESR1 Estrogen receptor positive
Exemestane Oncology ESR1 Estrogen receptor positive
(continued)

4 Pharmacogenetics